Collegium Pharmaceutical (COLL) FCF Margin (2016 - 2026)

Collegium Pharmaceutical has reported FCF Margin for 11 years, with the latest figure at 35.44% in Q2 2026.

• On a quarterly basis, FCF Margin fell 306.0% year-over-year to 35.44% in Q2 2026; TTM through Jun 2026 was 40.62%, a 1207.0% increase from a year earlier, with the FY2025 full-year figure at 41.97%, up 977.0% from the prior year.
• FCF Margin was 35.44% for Q2 2026 at Collegium Pharmaceutical, up from 29.37% in the prior quarter.
• The five-year high for FCF Margin was 73.53% in Q2 2023, with the low at 30.36% in Q1 2022.
• Average FCF Margin over 5 years is 35.42%, with a median of 37.94% recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 8392 bps in 2022, then soared 4935 bps in 2023.
• Over 5 years, FCF Margin stood at 46.49% in 2022, then gained by 5 bps to 48.87% in 2023, then retreated by 5 bps to 46.21% in 2024, then advanced by 29 bps to 59.56% in 2025, then sank by 41 bps to 35.44% in 2026.
• The last three FCF Margin figures came in at 35.44% (Q2 2026), 29.37% (Q1 2026), and 59.56% (Q4 2025), per Business Quant data.